146 related articles for article (PubMed ID: 33297847)
21. Rapid infusion of rituximab over 60 min.
Tuthill M; Crook T; Corbet T; King J; Webb A
Eur J Haematol; 2009 Apr; 82(4):322-5. PubMed ID: 19220420
[TBL] [Abstract][Full Text] [Related]
22. Rapid infusion rituximab for maintenance therapy: is it feasible?
Patel J; Ho M; Ho V; Bello C; Djulbegovic B; Sokol L; Wetzstein G
Leuk Res Treatment; 2013; 2013():629283. PubMed ID: 24288618
[TBL] [Abstract][Full Text] [Related]
23. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
24. Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution.
Atay S; Barista I; Gundogdu F; Akgedik K; Arpaci A
J Oncol Pract; 2012 May; 8(3):141-3. PubMed ID: 22942806
[TBL] [Abstract][Full Text] [Related]
25. Rapid-Infusion Rituximab in a Pediatric Population.
Gaffney KJ; Dahl EM; Stanton MP; Starek E; Zembillas AS
J Pediatr Pharmacol Ther; 2020; 25(3):215-219. PubMed ID: 32265604
[TBL] [Abstract][Full Text] [Related]
26. Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count.
Plante M; Garneau L; Laprise-Lachance M; Lemieux P; Dorval M
Curr Oncol; 2021 Oct; 28(5):4118-4128. PubMed ID: 34677267
[TBL] [Abstract][Full Text] [Related]
27. Rapid rituximab administration: Safety of 60-minute infusions in malignant and benign haematological disease.
Whiting R; Misko J; McGuire M; Fox E
J Oncol Pharm Pract; 2024 Jun; ():10781552241260863. PubMed ID: 38847136
[TBL] [Abstract][Full Text] [Related]
28. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation.
Usui M; Isaji S; Mizuno S; Sakurai H; Uemoto S
Clin Transplant; 2007; 21(1):24-31. PubMed ID: 17302588
[TBL] [Abstract][Full Text] [Related]
29. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
30. Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center.
Kowalski KE; Adams CB; Voils SA; Wheeler SE
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):723-728. PubMed ID: 31530473
[TBL] [Abstract][Full Text] [Related]
31. Rapid rituximab infusion is safe and well tolerated in malignant and benign disease.
Ursu SG; Rinchuse DL; Lister J
J Oncol Pharm Pract; 2021 Dec; 27(8):1919-1922. PubMed ID: 33287667
[TBL] [Abstract][Full Text] [Related]
32. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
Salar A; Casao D; Cervera M; Pedro C; Calafell M; Abella E; Alvarez-Larrán A; Besses C
Eur J Haematol; 2006 Oct; 77(4):338-40. PubMed ID: 16856919
[TBL] [Abstract][Full Text] [Related]
33. Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan.
Yokoyama M; Terui Y; Takeuchi K; Nara E; Nakano K; Ueda K; Nishimura N; Mishima Y; Sakajiri S; Tsuyama N; Ozawa K; Hatake K
ISRN Oncol; 2013; 2013():863909. PubMed ID: 23691364
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma.
Gutiérrez A; Rodríguez J; Martínez J; Amezaga R; Ramos R; Galmes B; Bea MD; Ferrer J; Pons J; Sampol A; Morey M; Duran MA; Raurich J; Besalduch J
Leuk Lymphoma; 2006 Jan; 47(1):111-5. PubMed ID: 16321834
[TBL] [Abstract][Full Text] [Related]
35. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
[TBL] [Abstract][Full Text] [Related]
38. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
39. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
40. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Byrd JC; Waselenko JK; Maneatis TJ; Murphy T; Ward FT; Monahan BP; Sipe MA; Donegan S; White CA
J Clin Oncol; 1999 Mar; 17(3):791-5. PubMed ID: 10071268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
